UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (47817) 47817
Newsletter (563) 563
Book Chapter (432) 432
Newspaper Article (354) 354
Magazine Article (226) 226
Dissertation (113) 113
Conference Proceeding (103) 103
Publication (51) 51
Book / eBook (33) 33
Web Resource (18) 18
Reference (16) 16
Book Review (5) 5
Government Document (4) 4
Journal / eJournal (3) 3
Trade Publication Article (2) 2
Transcript (2) 2
Data Set (1) 1
Paper (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (31533) 31533
science & technology (29203) 29203
life sciences & biomedicine (28540) 28540
male (19472) 19472
angiotensin-converting enzyme inhibitors - therapeutic use (18697) 18697
female (14710) 14710
animals (12694) 12694
biological and medical sciences (12475) 12475
medical sciences (10961) 10961
middle aged (10630) 10630
cardiovascular system & cardiology (9569) 9569
aged (8931) 8931
angiotensin-converting enzyme inhibitors - pharmacology (8787) 8787
hypertension - drug therapy (8322) 8322
adult (6976) 6976
angiotensin (6266) 6266
hypertension (6240) 6240
rats (6221) 6221
cardiac & cardiovascular systems (6107) 6107
pharmacology. drug treatments (5945) 5945
blood pressure - drug effects (5904) 5904
pharmacology & pharmacy (5290) 5290
angiotensin-converting enzyme inhibitors (5180) 5180
angiotensin converting enzyme (5114) 5114
abridged index medicus (5060) 5060
antihypertensive agents - therapeutic use (4685) 4685
cardiovascular system (4628) 4628
peripheral vascular disease (4331) 4331
risk factors (4222) 4222
heart failure - drug therapy (4200) 4200
angiotensin-converting enzyme inhibitors - adverse effects (4145) 4145
treatment outcome (3981) 3981
enzymes (3882) 3882
adrenergic beta-antagonists - therapeutic use (3840) 3840
angiotensin-converting enzyme inhibitors - administration & dosage (3719) 3719
drug therapy, combination (3556) 3556
ace inhibitors (3485) 3485
general & internal medicine (3463) 3463
renin-angiotensin system - drug effects (3326) 3326
heart failure (3272) 3272
medicine, general & internal (3243) 3243
hypertension - physiopathology (3171) 3171
blood pressure (3123) 3123
antihypertensive agents (3113) 3113
cardiology. vascular system (2917) 2917
peptidyl-dipeptidase a - metabolism (2882) 2882
angiotensin-converting enzyme (2742) 2742
time factors (2644) 2644
calcium channel blockers - therapeutic use (2538) 2538
peptidyl-dipeptidase a - genetics (2351) 2351
aged, 80 and over (2321) 2321
urology & nephrology (2319) 2319
diuretics - therapeutic use (2252) 2252
drug therapy (2202) 2202
research (2191) 2191
hypertension - complications (2190) 2190
captopril - pharmacology (2187) 2187
heart (2165) 2165
renin-angiotensin system (2152) 2152
angiotensin receptor antagonists (2149) 2149
analysis (2052) 2052
angiotensin ii type 1 receptor blockers - therapeutic use (1997) 1997
double-blind method (1954) 1954
fundamental and applied biological sciences. psychology (1940) 1940
angiotensin ii (1927) 1927
dose-response relationship, drug (1892) 1892
health aspects (1853) 1853
biochemistry & molecular biology (1802) 1802
renin-angiotensin system - physiology (1772) 1772
enalapril - therapeutic use (1763) 1763
follow-up studies (1761) 1761
heart failure - physiopathology (1728) 1728
retrospective studies (1711) 1711
antihypertensive agents - pharmacology (1697) 1697
care and treatment (1695) 1695
diabetes (1678) 1678
covid-19 (1667) 1667
mortality (1648) 1648
captopril (1630) 1630
prospective studies (1608) 1608
peptidyl-dipeptidase a (1551) 1551
clinical trials as topic (1550) 1550
angiotensin receptor antagonists - therapeutic use (1544) 1544
enzyme inhibitors (1543) 1543
randomized controlled trials as topic (1539) 1539
blood and lymphatic vessels (1531) 1531
captopril - therapeutic use (1527) 1527
prognosis (1525) 1525
rats, sprague-dawley (1499) 1499
hemodynamics - drug effects (1494) 1494
physiological aspects (1492) 1492
physiology (1484) 1484
mice (1449) 1449
adolescent (1416) 1416
sars-cov-2 (1414) 1414
cardiovascular disease (1410) 1410
rats, wistar (1390) 1390
kidney - drug effects (1389) 1389
angiotensin-converting enzyme 2 (1386) 1386
angiotensin-converting enzyme inhibitor (1372) 1372
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (45515) 45515
Japanese (1210) 1210
German (1053) 1053
French (770) 770
Russian (728) 728
Spanish (464) 464
Chinese (301) 301
Italian (271) 271
Portuguese (267) 267
Polish (233) 233
Korean (107) 107
Czech (89) 89
Danish (86) 86
Hungarian (84) 84
Dutch (79) 79
Swedish (64) 64
Norwegian (60) 60
Slovak (31) 31
Turkish (31) 31
Finnish (30) 30
Romanian (27) 27
Hebrew (23) 23
Ukrainian (23) 23
Serbian (18) 18
Croatian (15) 15
Lithuanian (14) 14
Persian (13) 13
Bosnian (4) 4
Bulgarian (4) 4
Slovenian (4) 4
Belarusian (1) 1
Indonesian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of pathology, ISSN 0022-3417, 06/2020, Volume 251, Issue 3, pp. 228 - 248
angiotensin-converting enzyme 2 (ACE2) | treatment | risk factors | pathology | MYOCARDIAL-INFARCTION | coronavirus disease 2019 (COVID-19) | SARS CORONAVIRUS | LUNG INJURY | CLINICAL CHARACTERISTICS | renin-angiotensin-aldosterone system (RAAS) | BLOOD-PRESSURE | ACUTE-RESPIRATORY-SYNDROME | RENAL ACE2 EXPRESSION | severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | pathophysiology | organ involvement | SEX-DIFFERENCES | FUNCTIONAL RECEPTOR | UP-REGULATION | severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) | renin–angiotensin–aldosterone system (RAAS) | coronavirus disease 2019 (COVID‐19) | angiotensin‐converting enzyme 2 (ACE2) | Pathology | Oncology | Life Sciences & Biomedicine | Science & Technology | Antiviral Agents - pharmacology | Pandemics | Age Factors | Pneumonia, Viral - therapy | Humans | Pneumonia, Viral - pathology | Risk Factors | Coronavirus Infections - physiopathology | Renin-Angiotensin System - genetics | Disease Progression | Metabolic Syndrome - complications | Morbidity | Pneumonia, Viral - physiopathology | COVID-19 | Angiotensin-Converting Enzyme 2 | Cardiovascular Diseases - complications | SARS-CoV-2 | Coronavirus Infections - virology | Betacoronavirus - physiology | Coronavirus Infections - therapy | Coronavirus Infections - pathology | Peptidyl-Dipeptidase A - metabolism | Sex Factors | Pneumonia, Viral - virology | Antiviral agents | Enzymes | Corticosteroids | Severe acute respiratory syndrome | Angiotensin | Physiological aspects | Coronaviruses | Biological response modifiers | Aldosterone | Health aspects | ACE inhibitors | Risk factors | Pathophysiology | Therapeutic applications | Clinical trials | Infections | Severe acute respiratory syndrome coronavirus 2 | Renin | Angiotensin II | Cardiovascular diseases | Metabolic disorders | Index Medicus
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2020, Volume 323, Issue 18, pp. 1769 - 1770
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2018, Volume 71, Issue 13, pp. 1474 - 1482
angioedema | blood pressure | heart failure | chronic kidney disease | left ventricular hypertrophy | angiotensin receptor blocker | coronary heart disease | adverse events | cough | diabetes | hypertension | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Angioedema - epidemiology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Hypertension - drug therapy | Renin-Angiotensin System - physiology | Antihypertensive Agents - therapeutic use | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Animals | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - epidemiology | Angioedema - chemically induced | Renin-Angiotensin System - drug effects | Blood Pressure - drug effects | Blood Pressure - physiology | Cardiovascular Diseases - chemically induced | Clinical Trials as Topic - methods | Hypertension - epidemiology | Drug Therapy, Combination | Angiotensin Receptor Antagonists - therapeutic use | Angiotensin Receptor Antagonists - adverse effects | Myocardial infarction | Angiotensin-converting enzyme inhibitors | Heart | End-stage renal disease | Enzyme inhibitors | Peptidyl-dipeptidase A | Blood pressure | Cardiology | Drug therapy | Heart diseases | Hypertension | Cerebral infarction | Stroke | Angioedema | Mortality | Risk analysis | Disease control | Patients | Inhibitors | Angiotensin | Renal failure | Infarction | Kidney diseases | Diabetes | Cardiovascular diseases | ACE inhibitors
Journal Article
Journal Article
Journal of neurochemistry, ISSN 0022-3042, 10/2010, Volume 115, Issue 1, pp. 47 - 57
insulin‐degrading enzyme | Alzheimer’s disease | neprilysin | β‐amyloid | Alzheimer’s disease brain | amyloid‐degrading enzymes | degradation | endothelin‐converting enzyme | insulin-degrading enzyme | Alzheimer's disease brain | endothelin-converting enzyme | Alzheimer's disease | amyloid-degrading enzymes | β-amyloid | Biochemistry & Molecular Biology | Neurosciences | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Neurology | Organic mental disorders. Neuropsychology | Psychology. Psychoanalysis. Psychiatry | Adult and adolescent clinical studies | Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases | Psychopathology. Psychiatry | Biological and medical sciences | Medical sciences | Metalloendopeptidases - genetics | Tissue Banks | Prospective Studies | Aspartic Acid Endopeptidases - biosynthesis | Humans | Brain - enzymology | Insulysin - biosynthesis | Male | Aspartic Acid Endopeptidases - genetics | Gene Expression Regulation, Enzymologic - physiology | Neprilysin - biosynthesis | Endothelin-Converting Enzymes | RNA - genetics | Synaptophysin - genetics | Amyloid beta-Peptides - genetics | Aged, 80 and over | Female | Neprilysin - genetics | Alzheimer Disease - psychology | Brain Chemistry - genetics | Cognition Disorders - enzymology | Amyloid beta-Peptides - biosynthesis | Electrophoresis, Polyacrylamide Gel | Cognition Disorders - genetics | DNA Primers | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Metalloendopeptidases - biosynthesis | RNA - biosynthesis | Gene Expression Regulation, Enzymologic - genetics | Synaptophysin - biosynthesis | Alzheimer Disease - metabolism | Indicators and Reagents | Insulysin - genetics | Aged | Alzheimer Disease - genetics | Medical colleges | Brain | Messenger RNA | Proteases | Pharmacy | Fluorescence | Public health | Target marketing | Neurochemistry | Proteins | Enzymes | Alzheimers disease | Ribonucleic acid--RNA | Index Medicus | AD brain | Alzheimer’s disease (AD) | endothelin converting enzyme (ECE) | insulin degrading enzyme (IDE) | Amyloid degrading enzymes | neprilysin (NEP) | β-amyloid (Aβ)
Journal Article